Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Sulfonamides. Found 8 abstracts

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Doss M, Kolb HC, Walsh JC, Mocharla VP, Zhu Z, Haka M, Alpaugh RK, Chen DY, Yu JQ. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. Mol Imaging Biol. 2014 Oct;16(5):739-46.
Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncol Rep. 2012 May;27(5):1400-6.
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib to decrease urinary retention associated with prostate brachytherapy. Brachytherapy. 2003 Jan;2(2):103-7.
Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer letters. 2002 Oct 08;184(1):7-12.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Sulfonamides

Sulfonamides Female therapeutic use Male pathology Anticarcinogenic Agents Kidney Neoplasms Pyrimidines Sprague-Dawley Rats Middle Aged Renal Cell Carcinoma Aged Rats Adult Nephrons Pyrroles Organ Sparing Treatments Prostaglandin-Endoperoxide Synthase Disease Progression therapy pc [Prevention & Control] Isoenzymes genetics Cyclooxygenase Inhibitors Nephrectomy Non-Steroidal Anti-Inflammatory Agents chemically induced Angiogenesis Inhibitors Carcinogenesis Experimental Mammary Neoplasms Neoplasm Metastasis Indoles Methylnitrosourea methods Healthy Volunteers Pazopanib 0 (15-deoxyprostaglandin J2) Prostatic Neoplasms rt [Radiotherapy] Radiometry en [Enzymology] 0 (Anticarcinogenic Agents) et [Etiology] prevention & Brachytherapy Treatment Outcome 363-24-6 (Dinoprostone) dt [Drug Therapy] Prostaglandin D2 Colonic Neoplasms Neoplasms Prostheses and Implants Animal Head and Neck Neoplasms 0 (Isoenzymes) Cell Division Urinary Bladder Neoplasms ci [Chemically Induced] 0 (Transcription Factors) me [Metabolism] Human ad [Administration & Dosage] Tyrosine kinase inhibitor Carbonic Anhydrases EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Apoptosis Intestinal Neoplasms pd [Pharmacology] 61-90-5 (Leucine) Cyclooxygenase 2 Inhibitors chemical synthesis de [Drug Effects] Knockout Mice Tetrahydronaphthalenes mt [Methods] Antineoplastic Combined Chemotherapy Protocols X-Ray Computed Tomography Dipeptides metabolism Cell Cycle di [Diagnosis] Non-US Gov't Support Pyrazoles Immune checkpoint inhibitor Cytoplasmic and Nuclear) 0 (Receptors 0 (Carcinogens) Sunitinib ag [Agonists] Fluorenes Drug Dose-Response Relationship Neoplasm Antigens 169590-42-5 (celecoxib) 0 (Cyclooxygenase Inhibitors) pharmacology Drug Synergism Antiangiogenic Unsaturated Fatty Acids 684-93-5 (Methylnitrosourea) Foreign-Body Reaction toxicity chemistry 80 and over Aged Dietary Fats pharmacokinetics Animal Mammary Neoplasms aa [Analogs & Derivatives] EC 1-14-99-1 (cyclooxygenase 2) Inbred F344 Rats Leucine Nivolumab drug therapy ph [Physiology] antagonists & inhibitors Transcription Factors administration & dosage ae [Adverse Effects] Mice Tissue Distribution tu [Therapeutic Use] Urinary Retention Carcinogens 35661-60-0 (N-(fluorenyl-9-methoxycarbonyl)leucine) Unsaturated Dietary Fats Positron-Emission Tomography 0 (Sulfonamides) 41598-07-6 (Prostaglandin D2) Cytoplasmic and Nuclear Receptors Metastatic renal cell carcinoma 0 (Fluorenes) ai [Antagonists & Inhibitors] control Animal Disease Models prevention & control bi [Biosynthesis] Dinoprostone
Last updated on Friday, January 03, 2020